NCT01084876View on ClinicalTrials.gov

Demonstrate Efficacy and Safety of Metastatic Breast Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

475

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

March 31, 2015

Conditions

Metastatic Breast Cancer

Interventions

DRUG

CT-P6

Administered every 3 weeks

DRUG

Herceptin

Administered every 3 weeks

DRUG

Paclitaxel

Administered every 3 weeks

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Celltrion

INDUSTRY